1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Takeda Looks To Ride 'Wave 1' To JPY5tn Target

12 NMEs Set For Mid-Term Launch

 
• By Ian Haydock

Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.

Hokusai Wave
Takeda Looks To Ride Wave 1 Pipeline • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. highlighted its “Wave 1” pipeline at its latest R&D day, saying it sees the group of 12 new molecular entities – all currently expected to be launched by the end of fiscal 2024 – helping drive total group revenues to the JPY5,000bn ($48bn) level by the end of fiscal 2030.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.